The hydrolysis of last resort carbapenem antibiotics by Klebsiella pneumoniae carbapenemase-2 (KPC-2) presents a significant danger to global health. Combined with horizontal gene transfer, the emergence KPC-2 threatens to quickly expand carbapenemase activity to ever increasing numbers of pathogens. Our understanding of KPC-2 has greatly increased over the past decade thanks, in great part, to 20 crystal structures solved by groups around the world. These include apo KPC-2 structures, along with structures featuring a library of 10 different inhibitors representing diverse structural and functional classes. Herein we focus on cataloging the available KPC-2 structures and presenting a discussion of key aspects of each structure and important relationships between structures. Although the available structures do not provide information on dynamic motions with KPC-2, and the family of structures indicates small conformational changes across a wide array of bound inhibitors, substrates, and products, the structures provide a strong foundation for additional studies in the coming years to discover new KPC-2 inhibitors.
Introduction
The development, mass production, and administration of antimicrobial drugs were a turning point in modern medicine. 1 At the start of the 20th century, infectious bacterial diseases were the leading causes of human mortality in the United States. 2 The clinical success of Penicillin G prompted an explosion of development of b-lactam drugs 3 that was immediately met with the spread of bacterial expression of b-lactamases, enzymes capable of hydrolyzing, and thereby inactivating, b-lactam drugs. Of the thousands of known b-lactamases, 4 carbapenemases are of particular concern due to their ability to hydrolyze last resort drugs. 5 Klebsiella pneumoniae carbapenemase-2 (KPC-2) is a serine b-lactamase that poses a significant threat to global health. 6, 7 This review details structural elements of KPC-2 and the nuanced structural changes observed for complexes of KPC-2 with inhibitors and natural substrates.
KPC-2 structural features
KPC-2 is a 293 amino acid protein in length exhibiting a mixed a and b structure. Although the mature protein is 28 kDa, the first 24 residues of the N-terminus comprise a signal peptide that designates the protein for secretory export. The overall architecture of KPC-2 ( Figure 1 ) is consistent with other class-A b-lactamases such as TEM b-lactamase (named after the initials of the original patient) and the sulfhydryl variant of TEM b-lactamase (SHV). 8 KPC-2 has two major sub-domains: one cluster of a-helices, and the other an aþb sandwich with a core of five b-strands. 9 The b-sheet of the aþb sandwich is formed by both the N and C terminal regions of the protein, while the a-helical subunit for KPC-2 sequentially lies between the outermost strands, 2 and 3, of the b-sheet. The aþb sandwich and a-helical cluster subdomains are tethered by a conserved disulfide bridge between C69 and C238 that is thought to contribute substrate specificity for
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10 as the resulting cleft between the aþb sandwich and a-helical cluster subdomains forms the active site of the enzyme. The active site itself is flanked by three loop regions. The loop region comprised of residues N214-H219 between a-helices a10 and a11 is homologous to the "hinge" region in TEM-1. 11 A second loop between a-helices a3 and a4 contains residue W105 at the periphery of the active site. The side chain of W105 engages in p-p stacking interactions with the penam rings of substrates. 12 While tryptophan is not conserved at position 105 across Class-A b-lactamases, these p-p stacking interactions play a role in substrate binding and specificity 13 and these interactions are conserved as W105 is replaced by histidine in Serratia marcescens enzyme 1 (SME-1) and tyrosine in both TEM-1 and SHV-1.
14,15 A third loop comprised of residues R164-D179 is known as the X-loop and is critical for catalytic activity and substrate specificity. 16, 17 The X-loop is highly conserved across Class-A b-lactamases 18 and is predicted to be a "hot spot" for mutations as bacteria respond to the evolutionary pressures of antibiotic use. The active site serine at position 70, by Ambler numbering, 19 is in close spatial proximity to K73, S130, and E166, residues identified as catalytically important for b-lactam hydrolysis.
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S130 itself is part of the "SDN" loop, highly conserved throughout the Class-A b-lactamases, consisting of residues S130-N132. 21 ,22 S130 protonates the b-lactam nitrogen after the b-lactam bond is broken and is reprotonated through a proton shuttling mechanism between K73 and E166. 20 N132 stabilizes the positive charge on K73 during catalysis and participates in hydrogen bonds that maintain the structural integrity of the active site. 20, 21 D131 coordinates an extensive hydrogen bond network that stabilizes the overall architecture of the active site. In the apo crystal structure of KPC-2, the sidechain of D131 interacts with residues in the a4 and a5 helices, thereby contributing to the position and stabilization of the loop containing W105. 9 The oxyanion hole (Figure 1 ), relatively conserved across the serine b-lactamases and thought to interact with the b-lactam ring carbonyl to facilitate orientation for hydrolysis, 23 is formed by the backbone nitrogen atoms of S70 and T237. 9 For KPC-2 and Ambler Class-A b-lactamases, the oxyanion hole is shallower compared to those of other serine b-lactamases, allowing KPC-2 and Ambler Class-A b-lactamases to accommodate a broader and bulkier spectrum of substrates. 9, 12 Immediately preceding T237 is the conserved KTG motif, found throughout Class-A b-lactamases, at positions K234-G236 on the b7 strand. 24 This KTG motif is typical of penicillin binding proteins 25, 26 and is spatially near an SXXK motif, Ambler positions 70-73, which harbors active site residues S70 and K73. 13 Interactions with substrates and inhibitors and observed structural changes X-ray crystal structures for KPC-2 deposited in the PDB can grouped into the following categories: (1) apo structures of KPC-2 including those without inhibitors or natural substrates and those that contain incidental ligands from crystallization conditions, (2) structures of KPC-2 complexed with boronic acid transition state analog inhibitors, (3) structures of KPC-2 with b-lactam substrates or hydrolyzed products, and (4) structures with diazabicyclooctane inhibitors. Table 1 lists details of KPC-2 structures deposited in the PDB and discussed in this review. We also direct the reader to the excellent review of b-lactamase inhibition 
Apo structures of KPC-2
The first crystal structure of KPC-2 became available in 2007 at 1.85 Å resolution. 9 Aside from being the first deposited, this structure was notable for the bicine molecules occupying the active site. The bicine carboxylates form hydrogen bonds with T235, T237, and S130 in KPC-2, 9 analogous to the interactions between the cefoxitin carboxylate and T316 observed in multiple structures of cefoxitin bound to the ampC b-lactamase (AmpC). 32 A similar interaction is utilized by the inhibitor SA2-13 for binding to SHV-1. 33 A year later in 2008, two additional crystal structures of KPC-2 were published at 1.6 Å and 1.23 Å resolution, respectively, 34 followed nine years later by a fourth apo KPC-2 structure deposited in 2017 at1.15 Å resolution. 35 The 2008 structure at 1.23 Å revealed a citrate anion in the active site featuring carboxylate group interactions between the ligand and T237, echoing the interactions discussed above. Similar active site interactions are also observed in other b-lactamase structures, often to sulfate anions as in the structures of Staphylococcus aureus penicillinase 1 (PC1), 36 TEM-1, 11 and Pseudomonas aeruginosa strain RNL-1 b-lactamase (PER-1). 37 Across the family of four KPC-2 structures, slight differences in the width of the active site are seen compared to the initial structure solved by Ke et al. 9 Petrella et al. 34 rationalized these differences as the result of crystal packing interactions and alignment of the four apo structures revealed a small C a RMSD of 0.42 Å . The differences between the four structures occur primarily at the N-and C-termini, with exception structure 5UL8 35 which also exhibits an altered conformation for G239 and a small shift of helix a3. Consistent between the structures is the relative accessibility of the catalytic S70 and the shallow active site, features which have been proposed as explanations for the broad spectrum of hydrolyzable substrates for KPC-2.
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Boronic acid transition state analogs Boronic acids and their derivatives are tetrahedral mimetics that have been explored as possible transition state analog inhibitors since the 1970s. 38, 39 Ambler Class-C b-lactamases can be inhibited using boronic acids, [40] [41] [42] and later research was conducted on boronic acids analogs of natural b-lactamase substrates 43 for several Class-A enzymes such as RTEM-1 (R-factor encoded TEM-1), 44 TEM-1, 45 and SHV. 46 The first published structure of a boronic acid transition state analog inhibitor (BATSI) for KPC-2 was a crystal structure of 3-nitrophenyl boronic acid (3-NPBA) complexed with KPC-2 at 1.62 Å (Figure 2(a) ). 28 Aligning the 3-NPBA complex with the apo KPC-2 structures results in a C a RMSD values less than 0.574 Å , respectively. 28 Although the structural changes upon ligand binding for these structures are small, relative to crystal structures of inhibitors and drugs bound to serine b-lactamases, the 3-NPBA bound structure reveals some differences. Compared to the prior structure of the AmpC/3-NPBA complex, 47 the orientation of the 3-NPBA 3-nitro group was suggested as incompatible with the active site of KPC-2 due to the orientation of N170. 28 In 2016, a second KPC-2 BATSI complex was solved, and this time resulting in a 1.87 Å structure with S02030 bound (Figure 2(b) ). 30 S02030 was of particular interest as it had shown inhibitory effects on the Class-C b-lactamase ADC-7. 48 Compared to structures of SHV-1 in complex with S02030, the KPC-2/S02030 complex exhibited two distinct conformers for the carboxyl-triazole moiety. 30 While SHV-1 has an arginine at position 244 which forms a salt bridge to the carboxyl-triazole, KPC-2 instead makes contacts with the carboxyl-triazole via S130, T235, and T237. Structures of one additional BATSI complexed with KPC-2 were deposited to the PDB in 2016 and released in 2018 under two separate accession codes (PDB codes: 5LL7 and 5MGI). The structures provide KPC-2 in complex with a phenyl boronic acid featuring a prop-2-enoic substituent (Figure 2(c) ). The carboxy moiety on the prop-2-enoic substituent makes contacts with the KPC-2 KTG motif, as well as S130. Ca alignment of 5LL7 with apo KPC-2 structure 3DW0 exhibits an RMSD value of 0.191 Å indicating minor structural changes upon BATSI complexation. Across these structures, the primary difference within for active site residues occurs for W105 which, when in complex with S02030, occupies a side chain rotamer that closes off the active site (Figure 2(d) ) relative to the orientations seen for KPC-2 in complex with 3-NPBA or the prop-2-enoic substituted phenylboronic acid.
b-lactam containing substrates and inhibitors
PSR-3-226 is a penam sulfone, a class of compounds including the drugs sulbactam 49 and tazobactam. 50 Studies of serine b-lactamase acylation by tazobactam discovered an imine or enamine intermediate as a key step, 51, 52 suggesting that a stabilized trans enamine might trap the enzyme in an inhibited state. 33 Thus, PSR-3-226 was intended to be an improvement on the SA2-13 inhibitor 53 that exploited this stabilized trans enamine. 33, 54 The KPC-2/PSR-3-226 complex was one of the first solved crystal structures of KPC-2 with an inhibitor. C a alignment of the KPC-2/PSR-3-226 structure with 3DW0 produced an RMSD of 0.158 Å 28 indicating that, with the notable exception of W105, the structure of KPC-2 with PSR-3-226 bound exhibited only minor changes relative to apo KPC-2. While movement of the W105 sidechain was pronounced, this Shurina and Page Influencing Klebsiella pneumoniae carbapenemase-2 structure 1599 rotation is consistent with a gating role for residues at this position (Figure 3(a) ). 15 The KPC-2/PSR-3-226 structure has served as a guidepost for further development of inhibitors for KPC-2 and other carbapenemases. In 2017, two additional structures of KPC-2 with hydrolyzed forms of b-lactam antibiotics were solved (Figure 3 ). These structures, solved at 1.45 Å and 1.4 Å resolution, respectively, represented the first enzyme-product complexes of a wild type serine b-lactamase. 35 Although prior structures of KPC-2 featured ligands acylated to S70, crystal structures for KPC-2 in complex with the hydrolyzed cephalosporin cefotaxime, and the hydrolyzed penem faropenem represented final products and were not covalently linked to KPC-2. Interestingly, for the KPC-2/hydrolyzed cefotaxime and KPC-2/hydrolyzed faropenem structures, the sidechain of the catalytic S70 has shifted into the oxyanion hole. 35 In comparison, prior apo structures found the sidechain of S70 is typically hydrogen bonded to K73, a residue suggested to function as a base in the initial acylation. 55, 56 The high energy conformation adopted by S70 shifted into the oxyanion hole was taken as evidence in support of previous proposed mechanisms for the expulsion of products from the active sites of other Class-A b-lactamases. 35 In this conformation, steric clashes and electrostatic repulsions of the newly generated hydroxyl group on hydrolyzed products had been proposed as primary drivers of product expulsion. 57, 58 Compared to acylated intermediates, 59 the KPC-2/hydrolyzed cefotaxime structure 35 and product complexes of active site mutants 60 indicate that the loss of additional hydrogen bonds to N132 may promote product expulsion and substrate turnover. 35 The rotation of S70 into the oxyanion hole in the KPC-2/hydrolyzed cefotaxime complex was also observed in the KPC-2 hydrolyzed Faropenem structure. Additionally, the rotation of the faropenem hydroxyethyl substituent away from N132 is of particular interest as the hydrogen bond between the hydroxyethyl substituent and N132 is cited as key factor in stabilization of carbapenems. [61] [62] [63] Faropenem complexes with noncarbapenamases, such as Citrobacter sedlakii b-lactamase (SED-1) (PDB code: 3BFF), feature hydrogen bonds with N132 and the active site deacylating water, preventing the carbapenem from being deacylated from the enzyme. 62, 64, 65 In the KPC-2, the faropenem hydroxyethyl group is able to rotate away from N132 due to the relatively Figure 3 . Panel A shows the active site of the PSR3-226 complex (PDB ID 3RXW). For clarity, the citrate molecules are not shown, and for W105 only the side chain rotamer corresponding to bound PSR3-226 is depicted. Panel B is a rendering of the hydrolyzed faropenem product (PDB ID 5UJ4). Two conformers for S130 are shown and the side chain of S70 is rotated into the oxyanion hole. Panel C is a rendering of the cefotaxime hydrolyzed product (PDB ID 5UJ3). The side chain of S70 is rotated into the oxyanion hole, which is thought to assist in expulsion of product from the active site. The wide and shallow active site of KPC-2 is readily accommodating of the comparatively bulky substituents within cefotaxime. Panel D is an overlay of the three structures from panels A-C. (A color version of this figure is available in the online journal.) ............................................................................................................................................................. enlarged active site and favorable van der Waals contacts with L167, a residue conserved across class A carbapenemases. 15 Diazabicyclooctane b-lactamase inhibitors Diazabicyclooctane (DABCO) compounds are a novel class of non b-lactam inhibitors of b-lactamases. Early development began in the mid-1990s 66 with initial focus placed on co-administration of DABCO inhibitors with conventional b-lactam-containing antibiotics, [67] [68] [69] [70] but recent DABCO b-lactamase inhibitors have also shown modest inhibition of penicillin binding proteins. 71 The first X-ray crystal structure of KPC-2 complexed with a DABCO, avibactam, was published in 2015. 72 Aside from the bridged DABCO center, avibactam was unique in that it lacked the carboxy group present in many of the ligands complexed with the active site in other KPC-2 structures (Figure 4) . 73 Avibactam is able to deacylate and recyclize, effectively regenerating an active inhibitor, 73 and is capable of inhibiting Class-A, -C, and -D b-lactamases, including KPC-2.
74 KPC-2 is unique relative to other b-lactamases in that KPC-2 also is capable of desulfating avibactam, 74 though the desulfation pathway is typically slow enough that effective treatment with avibactam is possible in bacterial infections expressing KPC-2. 72, 74 Potential changes in chirality about N1 in avibactam and a lack of hydrogen bonds between KPC-2 and N6 have been postulated as leaving avibactam prone to desulfation. 72 In 2015, Papp-Wallace et al. 29 found KPC mutants exhibiting signs of resistance to inhibition by avibactam. In the KPC-2/avibactam structure, the avibactam carbonyl occupies the oxyanion hole of KPC-2, while the Shurina and Page Influencing Klebsiella pneumoniae carbapenemase-2 structure 1601 sulfate group makes contacts with S130, T235, T237 much in the manner observed with prior structurally characterized ligands.
Six additional structures of KPC-2 complexed with three DABCO b-lactamase inhibitors were published in 2018 using both co-crystallization and soaking methods. 31 Two of the structures obtained through co-crystallization showed evidence of desulfation of the DABCO in the active site, whereas the soaking experiments did not exhibit desulfation. An overlay of each of the three new DABCO compounds with the KPC-2/avibactam structure showed similar active site architecture and binding geometries as those seen for the KPC-2/avibactam complex indicating a similar, if not identical mode of interaction with KPC-2. 31 Of note, however, is the added interaction between the carbonyl of C238 and the piperidine ring in zidebactam (previously known as WCK 5107).
Conclusions and outlook
The pursuit of structural information for KPC-2 and its interactions with antibiotics and inhibitors, spanning just over a decade, has been a clear success. With 20 KPC-2, X-ray crystal structures solved and deposited in the PDB, representing complexes of inhibitors that span multiple approaches of inhibition, and the field has been buoyed by a wealth of structural data for guiding the development of new b-lactamase inhibitors. Small structural variations between the active site of KPC-2 and other serine b-lactamases have enabled a broad swath of structures on different serine b-lactamases to provide compelling explanations as to how KPC-2 and similar carbapenamases are able to hydrolyze a broad spectrum of b-lactam-containing antibiotics and b-lactam-containing inhibitors. Subtle differences among these structures have even suggested mechanisms through which KPC-2 degrades non-b-lactam inhibitors such as Avibactam. 72 Despite this progress, there are several problems that remain unsolved due to the nature of KPC-2 and the limitations of crystallographic studies. First, the active site of KPC-2 is uniquely troublesome based on the tremendous number of substrates it is able to hydrolyze or otherwise degrade. The wide, shallow active site with an accessible catalytic serine is not readily perturbed by mainline inhibitors. Second, most of the observed structural changes in the active site of KPC-2 have been minute, 9, 28, 30, 31, 35, 72 often differing by only a single hydrogen bond or polar contact. While these insights from X-ray crystallography are important and have assisted in the development of new drugs, the library of current structures does not provide information on the dynamic motions of these structures, bonds, and interactions. Thankfully there are well established techniques for measuring dynamic parameters, such as NMR spectroscopy. 75, 76 Prior NMR dynamics experiments have been conducted on Class-A b-lactamases to investigate backbone dynamics, 77, 78 picosecond-nanosecond motions of active site residues, 76, 79, 80 and substrate binding. 81 Such approaches may assist in the development of allosteric b-lactamase inhibitors [82] [83] [84] for KPC-2, and when teamed with the extensive library of KPC-2 crystals, structures may open avenues to new inhibitors that target active site dynamics for inhibition. The future of KPC-2 inhibitor development for the next decade builds off a strong foundation of structural data, providing scientists with a crucial edge in the battle to combat carbapenem resistance.
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